ACADIA Pharmaceuticals Inc
โ€16.22ย โ€โ‚ฌ
15 ื‘ื™ื•ืœื™, 22:59:40 GMTโ€Ž+2โ€Ž · EUR · FRA · ื›ืชื‘ ื•ื™ืชื•ืจ
ืžื ื™ื”ื ื™ื™ืจ ืขืจืš ืฉืจืฉื•ื ื‘DEื”ืžืฉืจื“ ื”ืจืืฉื™ ืฉืœ ื”ื—ื‘ืจื” ื ืžืฆื ื‘ืืจื”"ื‘
ืฉืขืจ ืกื’ื™ืจื” ืงื•ื“ื
โ€16.11ย โ€โ‚ฌ
ื˜ื•ื•ื— ื™ื•ืžื™
โ€16.22ย โ€โ‚ฌ - โ€16.22ย โ€โ‚ฌ
ื˜ื•ื•ื— ืฉื ืชื™
โ€13.39ย โ€โ‚ฌ - โ€29.40ย โ€โ‚ฌ
ืฉื•ื•ื™ ืฉื•ืง
2.98Bโ€ USD
ื ืคื— ืžืกื—ืจ ืžืžื•ืฆืข
22.00
ืžื›ืคื™ืœ ืจื•ื•ื—
-
ืชืฉื•ืืช ื“ื™ื‘ื™ื“ื ื“
-
ื‘ื•ืจืกื” ืขื™ืงืจื™ืช
NASDAQ
ื‘ื—ื“ืฉื•ืช
ื›ืกืคื™ื
ื”ืฆื”ืจืช ื”ื›ื ืกื”
ื”ื›ื ืกื”
ืจื•ื•ื— ื ืงื™
(USD)ืžืจืฅ 2024ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ื”ื›ื ืกื”
205.83Mโ€73.75%
ื”ื•ืฆืื•ืช ืชืคืขื•ืœื™ื•ืช
107.99Mโ€6.67%
ืจื•ื•ื— ื ืงื™
16.56Mโ€138.48%
ืฉื•ืœื™ ืจื•ื•ื— ื ืงื™
8.04122.14%
ืจื•ื•ื—ื™ื ืœืžื ื™ื”
0.10137.04%
ืจื•ื•ื— ืœืคื ื™ ืจื™ื‘ื™ืช, ืžื™ืกื™ื, ืคื—ืช ื•ื”ืคื—ืชื•ืช
20.74Mโ€139.01%
ืฉื™ืขื•ืจ ืžืก ืืคืงื˜ื™ื‘ื™
21.17%โ€”
ืกืš ื›ืœ ื”ื ื›ืกื™ื
ื—ื‘ื•ืช ื›ื•ืœืœืช
(USD)ืžืจืฅ 2024ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ืžื–ื•ืžื ื™ื ื•ื”ืฉืงืขื•ืช ืœื˜ื•ื•ื— ืงืฆืจ
470.52Mโ€16.79%
ืกืš ื›ืœ ื”ื ื›ืกื™ื
855.10Mโ€30.49%
ื—ื‘ื•ืช ื›ื•ืœืœืช
391.06Mโ€39.14%
ื”ื•ืŸ ืขืฆืžื™ ื›ื•ืœืœ
464.04Mโ€โ€”
ื”ื•ืŸ ืขื•ืžื“
165.22Mโ€โ€”
ืžื›ืคื™ืœ ื”ื•ืŸ
5.73โ€”
ืชืฉื•ืื” ืขืœ ื”ื ื›ืกื™ื
4.74%โ€”
ืชืฉื•ืื” ืขืœ ื”ื•ืŸ
7.51%โ€”
ืฉื™ื ื•ื™ ื‘ืฉื•ื•ื™ ืžื–ื•ืžื ื™ื
(USD)ืžืจืฅ 2024ืฉื™ื ื•ื™ ืžืฉื ื” ืœืฉื ื”
ืจื•ื•ื— ื ืงื™
16.56Mโ€138.48%
ืžื–ื•ืžื ื™ื ืžืคืขื™ืœื•ืช ืฉื•ื˜ืคืช
29.08Mโ€262.15%
ืžื–ื•ืžืŸ ืžื”ืฉืงืขื•ืช
โ€Ž-14.04Mโ€โ€Ž-107.29%
ืžื–ื•ืžืŸ ืžืžื™ืžื•ืŸ
1.04Mโ€โ€Ž-28.85%
ืฉื™ื ื•ื™ ื‘ืฉื•ื•ื™ ืžื–ื•ืžื ื™ื
16.09Mโ€โ€Ž-90.86%
ืชื–ืจื™ื ืžื–ื•ืžื ื™ื ืคื ื•ื™
77.56Mโ€8.36%
ืžื™ื“ืข ื›ืœืœื™
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Wikipedia
ืชืืจื™ืš ื”ืงืžื”
1993
ืืชืจ
ืขื•ื‘ื“ื™ื
610
ืžื ื™ื•ืช ื ื•ืกืคื•ืช
ืžื ื™ื•ืช ืฉืขืฉื•ื™ื•ืช ืœืขื ื™ื™ืŸ ืื•ืชืš
ื”ืจืฉื™ืžื” ื”ื–ื• ื ื•ืฆืจืช ืžื—ื™ืคื•ืฉื™ื ืื—ืจื•ื ื™ื, ืžื ื™ื™ืจื•ืช ืขืจืš ื‘ืžืขืงื‘ ื•ืžืคืขื™ืœื•ื™ื•ืช ืื—ืจื•ืช. ืžื™ื“ืข ื ื•ืกืฃ

ื›ืœ ื”ื ืชื•ื ื™ื ื•ื”ืžื™ื“ืข ืžืกื•ืคืงื™ื ื‘ืฆื•ืจืชื ื”ืžืงื•ืจื™ืช ืœืžื˜ืจื•ืช ืื™ื ืคื•ืจืžื˜ื™ื‘ื™ื•ืช ืื™ืฉื™ื•ืช ื‘ืœื‘ื“, ื•ืœื ื ื•ืขื“ื• ืœืกืคืง ื™ื™ืขื•ืฅ ื›ืœื›ืœื™ ืื• ืœืžื˜ืจื•ืช ืžืกื—ืจ, ื”ืฉืงืขื”, ืžื™ืกื•ื™, ืžืฉืคื˜, ื—ืฉื‘ื•ื ืื•ืช ืื• ื›ืœ ื™ื™ืขื•ืฅ ืื—ืจ. Google ืื™ื ื” ืžืฆื™ืขื” ื™ื™ืขื•ืฅ ื”ืฉืงืขื•ืช ืื• ื™ื™ืขื•ืฅ ืคื™ื ื ืกื™ ื•ืื™ื ื” ืžื‘ื™ืขื” ืขืžื“ื”, ื”ืžืœืฆื” ืื• ื“ืขื” ื›ืœืฉื”ื™ ื‘ื›ืœ ื”ืงืฉื•ืจ ืœื›ืœ ืื—ืช ืžื”ื—ื‘ืจื•ืช ื”ื›ืœื•ืœื•ืช ื‘ืจืฉื™ืžื” ื–ื•, ืื• ืœื ื™ื™ืจื•ืช ื”ืขืจืš ืฉืžื•ื ืคืงื™ื ืขืœ ื™ื“ื™ ื—ื‘ืจื•ืช ืืœื”. ื™ืฉ ืœื”ืชื™ื™ืขืฅ ืขื ืกื•ื›ืŸ ื”ืžื ื™ื•ืช ืื• ื”ื™ื•ืขืฅ ื”ืคื™ื ื ืกื™ ืฉืœืš ื›ื“ื™ ืœืืžืช ืืช ื”ืชืžื—ื•ืจ ืœืคื ื™ ื‘ื™ืฆื•ืข ืขืกืงืช ืกื—ืจ. ืžื™ื“ืข ื ื•ืกืฃ
ื—ื™ืคื•ืฉ
ื ื™ืงื•ื™ ื”ื—ื™ืคื•ืฉ
ืกื’ื™ืจืช ื”ื—ื™ืคื•ืฉ
ืืคืœื™ืงืฆื™ื•ืช Google
ื”ืชืคืจื™ื˜ ื”ืจืืฉื™